(Vienna, 23 July 2026) The Medical University of Vienna has concluded a licence agreement with Nona Biosciences, a global biotechnology company for the use of H2L2 transgenic mouse technology. The agreement gives the inter-university Ignaz Semmelweis Institute, headed by Florian Krammer, access to a platform that can be used to generate fully human antibodies for research and development programmes.
Antibodies play a vital role in modern medicine and form the basis of numerous diagnostic applications and biotechnologically produced therapies. Nona’s H2L2 Harbour Mice technology is based on genetically modified mice that, following immunisation, produce antibodies with fully human structures. This enables fully human antibody candidates to be obtained and developed for further scientific investigation and potential medical applications.
Under the agreement, MedUni Vienna is granted the right to use Nona’s technology for antibody generation and to further develop the resulting antibodies and antibody products for research, diagnostic, and therapeutic applications. The H2L2 Harbour Mice platform and all associated intellectual property rights remain vested in Nona Biosciences.
“Access to this technology expands our capabilities to generate and characterise human antibodies against relevant biological targets, particularly viral spike proteins. This provides us with an additional foundation for the development of antiviral therapies, particularly with a view to future pandemics,” said Florian Krammer, Professor of Infectious Diseases at MedUni Vienna and Director of the inter-university Ignaz Semmelweis Institute.
“We are delighted to partner with the Medical University of Vienna. This collaboration underscores the power of our H2L2 Harbour Mice platform to accelerate the discovery of fully human antibodies against clinically relevant targets. By combining our technology with the scientific expertise of Prof. Krammer and his team at the Ignaz Semmelweis Institute, we aim to make meaningful contributions to antiviral therapeutic development and pandemic preparedness,” said Di Hong, Chief Executive Officer of Nona Biosciences.
The H2L2 technology complements MedUni Vienna’s existing research activities in the field of immunology and antibody research and strengthens the university’s international network through its collaboration with a specialist partner from the biotechnology sector.